Feds Award Novavax $1.6 Billion to Speed Up Virus Vaccine

The federal government has provided significant funding to accelerate COVID-19 vaccine testing and manufacturing, marking the largest award by the Trump Administration's Vaccine Development Initiative, Operation Warp Speed. The NovaVax vaccine, which uses coronavirus fragments to trigger an immune response, aims to deliver 100 million doses by January 2021. Despite not being listed among Operation Warp Speed finalists, NovaVax received unexpected funding, raising questions due to its lack of market history.

What is the primary goal of the federal government's funding in the context of COVID-19?

• To reduce the number of vaccine doses produced

• To enhance the speed of vaccine testing and manufacturing

• To focus solely on testing existing vaccines

• To slow down the vaccine development process

What unique approach does the NovaVax vaccine use to stimulate the immune system?

• It uses live coronavirus strains

• It uses a plant-based formula

• It uses microscopic coronavirus fragments

• It uses a traditional flu vaccine base

By when does NovaVax aim to deliver 100 million doses of their vaccine?

• By January 2021

• By the end of 2021

• By the end of 2020

• By mid-2021

What was surprising about the funding received by NovaVax?

• The company had previously rejected government funding

• The company was not listed among Operation Warp Speed finalists

• The company had already brought a product to market

• The company was already a market leader

Which publication first reported that NovaVax was not listed among the Operation Warp Speed finalists?

• The Washington Post

• The Wall Street Journal

• The New York Times

• The Guardian